Drug-Sensitized Yeast Platform Reveals Selective mTOR Inhibition

Study Background and Research Question

The mechanistic target of rapamycin (mTOR) pathway is a central regulator of cell growth, metabolism, and lifespan, making it a focal point in aging and cancer biology. Pharmacological inhibition of mTOR, especially via rapamycin, has been shown to extend lifespan in multiple model organisms. However, rapamycin and its analogs (rapalogs) are associated with potential off-target effects and immunosuppression, underscoring the need to discover more selective mTOR inhibitors. The initial discovery of TOR in Saccharomyces cerevisiae (yeast) laid the foundation for pathway-based drug screening. Yet, existing yeast models have limited sensitivity for identifying weak or structurally distinct TOR inhibitors. This led the authors to ask: can a genetically engineered, drug-sensitized yeast system improve the identification and characterization of novel mTOR inhibitors?

Key Innovation from the Reference Study

The primary innovation reported by Breen et al. (GeroScience, 2025) is a yeast-based platform with enhanced drug sensitivity for the discovery of compounds that specifically inhibit the TOR pathway. By engineering yeast strains with combined mutations in TOR pathway genes and removing 12 additional genes involved in drug efflux, the authors created a background that is highly receptive to exogenous compounds. This system enables detection of TOR-dependent growth inhibition by candidate molecules at concentrations orders of magnitude lower than required in wild-type yeast. The platform not only increases the throughput and sensitivity of screening but also discriminates between compounds that act directly on TOR and those with off-target effects.

Methods and Experimental Design Insights

The research team constructed a panel of yeast strains with strategic genetic modifications:

• Deletion of TOR1 to generate hypersensitivity to TORC1 inhibitors.
• Strains lacking FPR1 or containing a tor1-1 allele to confer resistance to rapamycin and related allosteric inhibitors.
• Removal of 12 drug-efflux genes, producing a background with increased intracellular accumulation of test compounds.

This genetically engineered platform was then employed to test a panel of known mTOR inhibitors (Torin1, GSK2126458/omipalisib, AZD8055) and a suite of additional small molecules, including Nebivolol hydrochloride, isoliquiritigenin, canagliflozin, withaferin A, ganoderic acid A, and taurine.

Protocol Parameters

• Yeast strain selection: Use strains with combined deletions in TOR pathway genes and key drug efflux pumps to maximize drug sensitivity.
• Compound dosing: In the drug-sensitized background, Torin1 and GSK2126458 showed TOR1-dependent inhibition at 100 nM and 500 nM, respectively, compared to 25 μM and 100 μM in wild-type strains.
• Growth inhibition assay: Monitor yeast proliferation in the presence of candidate compounds; compare growth in wild-type versus engineered strains to determine TOR pathway specificity.
• Control compounds: Include both positive controls (rapamycin, Torin1) and negative controls (β1-adrenoceptor antagonists such as Nebivolol hydrochloride) to benchmark selectivity.

Core Findings and Why They Matter

The drug-sensitized yeast platform demonstrated a dramatic increase in sensitivity for detecting TOR inhibitors. Specifically, Torin1 and GSK2126458/omipalisib required 200-fold and 250-fold lower concentrations, respectively, to elicit TOR1-dependent growth inhibition in the sensitized strains compared to wild-type. AZD8055, which showed no growth effect in wild-type yeast at 100 μM, produced clear TOR1-dependent sensitivity in the engineered background. The platform also identified aminophylline (a caffeine analog) as a TOR1-dependent inhibitor, refining the understanding of compound selectivity.

Importantly, Nebivolol hydrochloride and several other compounds exhibited no evidence of TOR inhibition in this system (reference study). This outcome is critical for cardiovascular pharmacology research, as it confirms that Nebivolol hydrochloride, a highly selective β1-adrenoceptor antagonist, does not produce off-target effects within the mTOR pathway in yeast models. Such pathway specificity enables more confident mechanistic studies on β1-adrenergic receptor signaling without confounding mTOR-related outcomes, as also discussed in related literature (structured guidance; mechanistic dossier).

Comparison with Existing Internal Articles

Internal resources have previously emphasized the pathway selectivity of Nebivolol hydrochloride for β1-adrenergic receptor signaling, noting its lack of mTOR pathway activity (translational insights). The current reference study provides direct experimental evidence using a highly sensitive yeast model, verifying that Nebivolol hydrochloride does not inhibit TOR, even at concentrations sufficient for detection of other kinase inhibitors. This aligns with the internal consensus: Nebivolol hydrochloride is an ideal tool for dissecting cardiovascular β1-adrenergic mechanisms without impacting mTOR-dependent cellular processes. Additionally, the yeast platform itself has been profiled in internal reviews (platform summary), which highlight its utility in clarifying the selectivity of both novel and established small molecules.

Limitations and Transferability

While the engineered yeast system offers exceptional sensitivity and throughput, several limitations must be considered. First, yeast models, though highly conserved in TOR signaling, may not fully recapitulate mammalian mTOR pathway complexity or compound pharmacodynamics. Second, the removal of drug efflux pathways, while beneficial for sensitivity, may not mirror human cell context, potentially exaggerating bioavailability effects. Lastly, the negative findings for Nebivolol hydrochloride and similar compounds are specific to yeast and may not exclude indirect effects in other systems. Nonetheless, as the study demonstrates, this platform is highly effective for initial selectivity screens and for ruling out direct mTOR-inhibitory activity in compounds intended for cardiovascular or metabolic research.

Research Support Resources

Researchers aiming to delineate β1-adrenergic receptor signaling without confounding mTOR pathway effects can leverage high-quality, selective β1-adrenoceptor antagonists. Nebivolol hydrochloride (SKU B1341) from APExBIO is validated as a potent and pathway-specific tool, with no detectable TOR inhibition at concentrations relevant for cellular studies, as confirmed by the latest yeast-based screen. This supports its continued use in cardiovascular pharmacology and hypertension research workflows where specificity is paramount.